戻る Agenda
Progressing the Development of Disease-Modifying Medicines for the Prevention of Paediatric-Onset Prevalent Chronic Diseases
Session Chair(s)
Ane Sofie Böhm Nielsen, MA, MPA
VP, Regulatory Policy & Intelligence
Novo Nordisk A/S, Denmark
This session will focus on the importance of early availability of novel medicines for children and adolescents facing early onset of serious chronic diseases. The panel will discuss how to progress the clinical development with the aim to bring us a step closer to providing such transformative medicines to children earlier than typically today.
Speaker(s)
Cécile Mathilde Ollivier, MS
Critical Path Institute, Netherlands
Vice President, Global Affairs - Managing Director, Europe
Kyle Jacques Rose
Patient, United States
Patient
Veerle Vanhuyse
Communication Representative INNODIA, Belgium